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Doxorubicin (DOX) is an anticancer drug widely used to treat human and non-human tumors but the late and 47 
persistent cardio-toxicity reduces the therapeutic utility of the drug. The full mechanism(s) of DOX-induced 48 
acute, sub-chronic and delayed toxicity, which has a preponderant mitochondrial component, remains unclear; 49 
therefore, it is clinically relevant to identify early markers to identify patients who are predisposed to DOX-50 
related cardiovascular toxicity. 51 
To address this, Wistar rats (16 weeks old) were treated with a single DOX dose (20 mg/Kg, i.p.); then, 52 
mRNA, protein levels and functional analysis of mitochondrial end-points were assessed 24 h later in the 53 
heart, liver and kidney. Using an exploratory data analysis, we observed cardiac-specific alterations after 54 
DOX treatment for mitochondrial Complexes III, IV, and preferentially for Complex I. Conversely, the same 55 
analysis revealed Complex II alterations are associated with DOX response in the liver and kidney. 56 
Interestingly, H2O2 production by the mitochondrial respiratory chain as well as loss of calcium-loading 57 
capacity, markers of sub-chronic toxicity, were not reliable indicators of acute DOX cardiotoxicity in this 58 
animal model.  59 
By using sequential Principal Component Analysis and Feature Correlation Analysis, we demonstrated for the 60 
first time alterations in sets of transcripts and proteins, but not functional measurements, that might serve as 61 
potential early acute markers of cardiac-specific mitochondrial toxicity, contributing to explain the trajectory 62 






Doxorubicin (DOX) is an anthracycline antibiotic that is widely used as a chemotherapeutic agent to treat 66 
multiple types of cancers (Simunek et al., 2009; Sterba et al., 2013); however, its therapeutic utility is limited 67 
due to the development of a cumulative and dose-dependent cardiotoxicity (Wallace, 2007). Congestive heart 68 
failure after DOX treatment is a pressing concern. The mortality observed after a chronic treatment can be as 69 
high as 50% (Chatterjee et al., 2010), increasing significantly for cumulative doses higher than 500 mg/m2 as 70 
reported by Singal et al. (1998). This life-time cumulative dose is equivalent to 13.5 mg/Kghumans or 83.8 71 
mg/Kgrats, using reference values and calculations suggested by Nair et al. (2016). The etiology of DOX-72 
induced cardiotoxicity is commonly ascribed to a redox-cycling of the drug on Complex I of the 73 
mitochondrial respiratory chain (Davies et al., 1986). Reactive oxygen species (ROS) generated during this 74 
process are believed to be responsible for the toxic effects on cardiac mitochondria, resulting in impaired 75 
oxidative phosphorylation (Santos et al., 2002), loss of mitochondrial calcium homeostasis (Zhou et al., 76 
2001a) and increased apoptotic signaling (Childs et al., 2002). DOX cardiotoxicity can present distinct 77 
phenotypes depending on the time elapsed since the initial treatment. Among the wide range of treatment 78 
protocols used in different laboratories (Ascensao et al., 2012; Hayward et al., 2007; Solem et al., 1996; Zhou 79 
et al., 2001c) we have previously demonstrated that treating Wistar rats with DOX resulted in toxicity only in 80 
the cardiac tissue and more easily detected in a sub-chronic treatment protocol (Pereira et al., 2012).  81 
A distinguishing feature is the fact that DOX toxicity presents a delayed component, manifesting itself years 82 
or even decades after treatment (Steinherz et al., 1991). Despite the abundant research in the last decades, the 83 
mechanism(s) underlying delayed DOX cardiac toxicity evolution are still far from being understood. 84 
Regardless the mechanism(s), it is clinically relevant to identify early signs of specific metabolic or 85 
transcriptional alterations observed after acute DOX treatment that may be considered early stress 86 
response(s). For this objective, we measured three distinct sets of data on cardiac, renal, and hepatic tissue in 87 
a rat model subjected to an acute DOX treatment (Ascensao, et al., 2012; Pereira, et al., 2012):  88 
(i) mRNA and protein levels of subunits of the mitochondrial respiratory complexes (I-IV), ATP synthase, 89 
and other relevant mitochondrial components (Cyt c, ANT, VDAC), and applied a suite of exploratory 90 




evidence of DOX-induced acute alterations that are present even in the absence of significant differences 92 
in the overall respiration flux (Pereira et al., 2016). 93 
(ii) hydrogen peroxide (H2O2) production by the mitochondrial respiratory chain. 94 
(iii) the sensitivity to the mitochondrial permeability transition (mPTP) as a surrogate of DOX response.  95 
Since the latter markers have both been detected in sub-chronic DOX toxicity animal models (Cappetta et al., 96 
2017; Zhou, et al., 2001c), our objective was to measure similar alterations in the acute model, with the 97 
novelty of performing experiments with both Complex I and II substrates. 98 
We used in this study a Wistar rat-based animal model and the acute treatment protocol previously described 99 
(Pereira, et al., 2012). A single dose of 20 mg/Kg DOX caused an increase in circulating troponin I and a ~ 100 
7.6 % decrease in cardiac mass with no visible alterations on the mitochondrial functional parameters 101 
evaluated. However, if a similar dosage was spanned over the period of 7 weeks (sub-chronic model), a clear 102 
mitochondrial impairment was observed (Pereira, et al., 2012; Zhou, et al., 2001a; Zhou et al., 2001b; Zhou, 103 
et al., 2001c), suggesting that DOX acute effects may progress into mitochondrial bioenergetic dysfunction. 104 
Moreover, it also suggests that the acute DOX toxicity model may be used to assess mitochondrial alterations 105 
that precede functional changes. Therefore, we included mitochondrial molecular parameters in the present 106 
study and anticipated that our novel approach will allow the assessment of early markers of acute DOX 107 
cardiotoxicity, facilitating the development of biomarkers to be used in the clinic for timely identification of 108 
patients with higher susceptibility to latent DOX toxicity and for the development of interventions aimed at 109 






Exploratory Data Analysis  113 
In the present research, we applied Principal Component Analysis (PCA) and Feature Correlation Analysis 114 
(FCA) to discover correlations and clustering patterns that help to identify relevant mitochondrial markers for 115 
the early detection of acute DOX toxicity. The small number of available samples prevents a complete and 116 
robust statistical analysis of the results. However, PCA provides initial insight regarding the separation of the 117 
treatment groups (Saline vs. DOX) allowing the discovery of important relevant trends. The twelve panels 118 
from Figure 1 illustrate the separation between Saline and DOX samples, for each of the 4 mitochondrial 119 
respiratory complexes in heart, kidney and liver tissues, respectively. To allow an informative 2D 120 
visualization we considered just the two principal components (explaining > 70% of the variance) and 121 
projected the original data in the lower dimensional space. 122 
Considering the cardiac tissue (Fig. 1a), the four panels representing each of the respiratory complexes tend to 123 
exhibit a clear separation between areas comprising samples from saline (blue area) and DOX-treated rats (red 124 
area). The separation is clearly visible for Complex I while some minor perturbations are observed in 125 
Complexes II, III, and IV. These minor differences correspond to specific regions where the separation is not 126 
evident, suggesting that it might be difficult for a computational analysis to accurately classify examples in 127 
these locations. Class separation between treatment groups for some respiratory complexes is also less evident 128 
when analyzing the remaining tissues in the study. For example, when analyzing the renal tissue (Fig. 1b) a 129 
visible class separation in Complexes II and III was observed, but the other complexes displayed several 130 
mixed sub-areas that might compromise the correct identification of the samples. Similarly, Complex II in the 131 
hepatic tissue (Fig. 1c) tends to generate a clear boundary between the two treatment groups, while the other 132 
complexes reveal several density sub-areas. 133 
Overall, PCA analysis of mRNA transcripts identified Complex I as preferable target for DOX acute toxicity 134 
in the heart while Complex II preferentially relates to DOX effects in the liver and kidney. Complexes III and 135 
IV are not robust markers to differentiate DOX toxicity in the analyzed tissues of this study. 136 
 137 
Next, we complemented the PCA with individual FCA, to estimate the dependence that may exist between 138 




exhibiting high sensitivity to DOX. Figure 2a-c show the global trend in the correlation changes resulting 140 
from DOX administration for features describing mRNA and protein levels in the heart, kidney and liver 141 
tissues, respectively.  142 
Observationally, there are some noticeable differences in the global patterns shown in Fig.2. In regard to liver 143 
(Fig. 2c), DOX administration tends to have a minor impact in the correlation strength change (high number 144 
of blank cells). Nonetheless, there is a high and consistent change involving the expression of subunit 145 
NDUFB8 in the liver. Conversely, Figures 2a and 2b, representing heart and kidney, respectively, exhibit a 146 
considerable number of filled cells identifying pairs with sizable correlation changes. The correlation change 147 
of NDUFB8 that was signaled in the liver is also present in these tissues, although to a lesser extent. 148 
Regarding features from Complex I, some additional correlation changes are observed, namely ND1 and ND2 149 
mRNA in the kidney and ND6 and NDUFS4 mRNA in the heart.  150 
In respect to Complex II, no noticeable changes in correlation were observed, regardless of the tissue in study. 151 
In Complex III related features, DOX treatment showed a stronger effect on the correlation change of CytB 152 
mRNA and UQCRFS1 protein levels in kidney. Finally, a few correlation changes regarding Complex IV 153 
features were also observed in heart and kidney, but not as obvious as reported above (Fig. S1). 154 
Overall, the FCA analysis suggests that the impact of the DOX treatment is easier to perceive if considering 155 
samples from heart and kidney when compared to liver, in agreement with findings obtained from PCA.  156 
 157 
Mitochondrial hydrogen peroxide production 158 
DOX-induced oxidative stress is considered a hallmark of its toxicity (Pereira, et al., 2012). In the present 159 
work, we investigate the contribution of different sites of the mitochondrial respiratory chain to the overall 160 
oxidative response by DOX. In respect to Complex I-sustained respiration, H2O2 production was similar to 161 
control values in heart and kidney mitochondria regardless of the energization conditions tested (Fig. 3a, c). 162 
However, in liver mitochondria, H2O2 production in the presence of rotenone was higher in mitochondria 163 
from DOX-treated animals (11 ± 3%) even though no statistical differences were observed in the presence of 164 
antimycin A alone (18 ± 10%) or with antimycin A plus rotenone (1 ± 2%). 165 
When mitochondria were energized with Complex II-linked substrates, heart mitochondria from DOX-treated 166 




significant (164 ± 72%, p = 0.06; Fig. 3a). Interestingly, this alteration was only observed in the absence of 168 
respiratory chain inhibitors as other conditions were similar to controls, reflecting ROS production through 169 
reverse electron transfer. 170 
In regard to liver and kidney, mitochondria from DOX-treated animals energized with Complex II-linked 171 
substrates presented similar levels of H2O2 production under all tested conditions (Fig. 3b, c). 172 
Overall, liver mitochondria from DOX-treated animals appear to generate more H2O2 compared to heart or 173 
kidney mitochondria but only when the respiratory chain is challenged by oxidative phosphorylation 174 
(OXPHOS) inhibitors, suggesting a higher flux of electrons through the respiratory chain at the Complex I 175 
level. 176 
 177 
Mitochondrial calcium loading capacity 178 
To assess mitochondrial calcium handling, we measured the sensitivity of each mitochondrial preparation to 179 
undergo the calcium-induced mPTP. Heart mitochondria from DOX-treated animals showed no alteration 180 
neither in calcium retention time nor release rate regardless of the respiratory substrate used (Fig. 4a). 181 
Similarly, no treatment-related effects on calcium flux were observed in kidney mitochondria (Fig. 4c). 182 
However, liver mitochondria from DOX-treated animals showed an apparent decreased sensitivity to mPTP 183 
opening (Fig. 4b). Hepatic mitochondrial preparations retained calcium for 43 ± 30% longer with Complex I-184 
linked respiration and 36 ± 19% for Complex II-linked respiration compared to control group although no 185 
statistical significance was observed (p = 0.194 and 0.098, respectively). In addition, calcium release rates 186 
were decreased by 49 ± 19% with Complex I-linked respiration and 18 ± 27% with Complex II-linked 187 
respiration. Significance was not always achieved due to the high variability in response to the treatment (Fig. 188 
4b). Confirming that all previous mentioned alterations were related to the mPTP opening is the fact that pre-189 
incubation with CsA, the classic mPTP desensitizer (Broekemeier et al., 1989) prevented calcium release 190 
(Table 1). 191 
Additionally, the same mitochondrial preparations were assessed for calcium-induced mitochondrial swelling 192 
in similar conditions to those aforementioned. Corroborating the above results, heart mitochondria swelling 193 
amplitude and swelling rate were not altered after acute treatment with DOX, regardless of the respiratory 194 




from control (Fig. 5c). However, liver mitochondria from DOX-treated animals appear to have slower 196 
swelling rate (6 ± 12% and 21 ± 37% for glutamate/malate and succinate, respectively; Fig. 5b) despite no 197 
apparent change in swelling amplitude (20 ± 30% and 11 ± 31% for glutamate/malate and succinate, 198 
respectively). As in calcium-loading capacity experiments, a high variability in response to the treatment was 199 
observed for liver mitochondria preventing any statistical differences. CsA under the experimental swelling 200 
conditions abolished all the effects, confirming the opening of the mPTP (Table 2). 201 
Two major regulators of the mPTP are: cyclophilin D (Cyp-D) in the matrix and ANT in the inner membrane 202 
(Silva et al., 2018). Cyp-D protein levels remained constant after the acute treatment regardless of the tissue 203 
analyzed (Table 3). We next measured mRNA and protein content of two ANT isoforms (Table 4). The 40 ± 204 
6% cardiac-specific decrease of ANT1 mRNA was significantly stronger than the effects observed in liver and 205 
kidney. Similarly, the 26 ±6% decrease of ANT2 mRNA was significant when compared to kidney. Still, no 206 
change in protein levels were observed after the 24 h treatment (Table 3). Moreover, no treatment- or tissue-207 
specific effects were detected regarding the protein and mRNA levels of VDAC, a porin of the outer 208 
mitochondrial membrane which governs ion and metabolites flux into mitochondria (Table 4). 209 
Overall, the sensitivity to mPTP opening remains constant in heart mitochondria after the acute treatment in 210 
contrast with liver mitochondria which show strong resistance to mPTP opening. However, this mPTP 211 
modulation cannot be attributed to changes in the protein levels of mPTP-related proteins. We suggest instead 212 






The mechanisms underlying DOX-selective cardiotoxicity remain undefined. Nevertheless, it is being 216 
more widely accepted that the antitumor activity is independent of cardiac toxicity, which may involve 217 
alterations of mitochondrial function (discussed in Pereira et al. (2011)). Acute DOX cardiac toxicity occurs 218 
during the early treatment of patients (high dose) and usually include symptoms which are therapeutically 219 
easy to manage and resolve once treatment is discontinued (Tokarska-Schlattner et al., 2006). Alternatively, a 220 
small, but significant number of patients develop chronic cardiotoxicity that can manifest itself at the end of 221 
treatment or several years later (Steinherz, et al., 1991). However, unlike acute toxicity, the dose-dependence 222 
together with its difficult early detection, renders DOX chronic toxicity life-threatening and largely 223 
uncontrolled. 224 
Regardless the mechanism(s) involved in DOX cardiotoxicity, the available data not only demonstrates 225 
mitochondrial involvement (Zhou, et al., 2001c), but also differences related to each treatment protocol (acute 226 
vs. sub-chronic in Pereira, et al. (2012)). Previously, by using Wistar rats treated with a single dose of DOX 227 
(20 mg/Kg), Ascensão et al. (2006; 2011; 2005) observed that heart mitochondria respiration and 228 
phosphorylation capacity were impaired after 24 h treatment. In contrast, we applied the same treatment 229 
protocol in younger rats of the same strain and observed no DOX effects on cardiac mitochondrial respiration, 230 
although minor, but statistical significant alterations were measured in ADP-stimulated respiration in liver 231 
(increase) and kidney (decreased) mitochondria (Pereira, et al., 2012), suggesting a differential response to 232 
DOX determined by age at time of treatment. Considering that a very large proportion of children with cancer 233 
are treated with DOX (van Dalen et al., 2009) despite its potential cardiotoxicity, it is relevant to identify 234 
early alterations of mitochondrial parameters/markers, which can be considered as early cardiac-specific 235 
stress responses to drug treatment. 236 
It has been demonstrated in different rat models that DOX sub-chronic treatment causes inhibition of 237 
mitochondrial respiration; oxidation of proteins, lipids, and nuclei acids; loss of cardiolipin and, alterations in 238 
the antioxidant enzymatic network (Oliveira et al., 2004; Oliveira et al., 2006; Pereira, et al., 2016; Wallace, 239 
1986; Zhou, et al., 2001b). Alterations of mitochondrial activity were also reported in different cardiac-like 240 
cell models, associated to increased cell death (Asensio-Lopez et al., 2016; Cunha-Oliveira et al., 2018; 241 




measured relevant mitochondrial mRNA and protein content, respiratory chain-derived H2O2, and calcium-243 
loading capacity in16-weeks old Wistar rats, suspecting that they would be reliable markers of DOX acute 244 
toxicity. 245 
Our data on calcium-loading capacity suggests that liver mitochondria are resistant to mPTP opening after 246 
DOX treatment in agreement with the increased mitochondrial bioenergetics fitness previously described by 247 
our lab (Ascensao, et al., 2011; Pereira, et al., 2012). Similarly, liver mitochondria displayed increased H2O2 248 
production when mitochondria were stressed by using OXPHOS inhibitors. Together with the improved 249 
mitochondrial fitness previously described, it suggests an increased electron flow through the respiratory 250 
chain. Electron flow has also been reported to modulate mPTP sensitivity (Fontaine et al., 1998), 251 
corroborating our data from calcium-loading capacity experiments. However, because a single timepoint was 252 
evaluated in our experimental setup (24 h), it was not possible to determine if DOX effect in liver 253 
mitochondria is slow to develop or long-lasting.  254 
Considering that increased mitochondrial oxidative stress and loss of calcium-loading capacity are 255 
regarded as hallmarks of chronic DOX-induced cardiac mitochondrionopathy (Pereira, et al., 2011; Zhou, et 256 
al., 2001a; Zhou, et al., 2001b; Zhou, et al., 2001c), our negative results in respect to cardiac tissue suggest 257 
that H2O2 generation and early loss of calcium-loading capacity following an acute DOX treatment are not 258 
reliable markers for early DOX cardiotoxicity. Therefore, it is relevant to identify alternative mitochondrial 259 
markers in order to recognize early functional or molecular signs of DOX-related cardiovascular toxicity. 260 
To this end, we also performed mRNA and protein analysis for components relevant for the maintenance of 261 
mitochondrial integrity and for OXPHOS. In general, mitochondrial-encoded transcripts showed minimal and 262 
heterogeneous increase in their levels compared to nuclear-encoded transcripts, demonstrating a preferential 263 
initial targeting of nuclear DNA. This is reminiscent of our previous data showing that DOX accumulates 264 
rapidly in the nucleus (Sardao, et al., 2009). Although the number of commercially available antibodies which 265 
worked in our setup was much lower than the total number of transcripts, we performed a similar analysis at 266 
the protein level, with at least one protein from each complex, semi-quantified by Western Blotting. No 267 
protein differences were found between saline and DOX-treated groups regardless of the analyzed tissue. This 268 




2008). Therefore, neither a direct correlation can be performed, nor treatment-related differences can be 270 
properly attributed through this analytic methodology. 271 
We complemented the study with an alternative strategy to analyze mRNA and protein data. From the 272 
PCA analysis, we obtained a consistent separation between treatment groups in the heart for all four 273 
respiratory complexes, suggesting that the effect of the DOX administration is clearly detected in this tissue. 274 
The boundary is particularly well defined when analyzing Complex I which was previously indicated as being 275 
inhibited in DOX-induced cardiotoxicity (Santos, et al., 2002). As for the other tissues, clear separations 276 
occur just in specific complexes: in liver there is a clear separation in Complex II, whereas in kidney clear 277 
boundaries are visible in Complexes II and III. This differential response of DOX suggests that the impact of 278 
treatment can be easily distinguished between the cardiac and other tissues such as the liver or kidney. 279 
Contrary to the absence or minimal changes in cardiac mitochondrial function (mPTP sensitivity, H2O2 280 
production and, respiration and oxidative stress markers (Pereira, et al., 2012)), the trends detected in the PCA 281 
study confirmed Complex I as the most promising target to detect acute mitochondrial changes resulting from 282 
DOX-treatment in the heart. Heart accumulates DOX slowly but to a higher extent than liver (Peters et al., 283 
1981) which could explain why DOX inhibitory effect on transcription was more easily detected in the heart, 284 
suggesting a tissue-specific concentration-dependent effect. Alternatively, these findings could be explained 285 
on the basis of tissue-specific stability of nuclear and mitochondrial-encoded mRNAs (Connor et al., 1996), 286 
being cardiac mRNAs less stable compared to the other tissues. Nonetheless, our data suggests that the 287 
observed mitochondrial molecular alterations precede changes in mitochondrial function. 288 
FCA allowed the identification of promising features that can be used for the detection of an acute 289 
toxicity. UQCRFS1 transcript and protein levels were involved in higher correlation changes in both kidney 290 
and heart. Complex III UQCRFS1subunit has been shown to be decreased in Barth syndrome animal models 291 
(Huang et al., 2015), a pathology which is associated to the development of cardiomyopathy (Dudek et al., 292 
2017). In addition to NDUFB8, NDUFS4 mRNA levels were also identified as features with high correlation 293 
changes in heart. Recently, Piekutowska-Abramczuk et al. (2018) reported NDUFB8 as the underlying gene 294 
in childhood-onset of Leigh-like encephalomyopathy, observing decreased NDUFS4 protein levels and lower 295 
Complex I activity as well. Interestingly, NDUFS4 is an accessory subunit important in Complex I assembly 296 




et al., 2016). NDUFB8 is not involved in the catalytic activity of Complex I but is an essential component of 298 
the membrane-anchor required for the full assembly of Complex I and contribute to the oligomerization of 299 
Complex I with Complex III and IV (Wu et al., 2016). Interestingly, we have previously suggested loss of 300 
mitochondrial supercomplexes as a possible underlying event in DOX-chronic toxicity (Pereira, et al., 2016). 301 
Our results indicate that an acute DOX treatment leads to alterations in proteins and transcripts related 302 
with Complexes I, III and IV in the heart and kidney, with a special predominance for Complex I. The liver 303 
tissue, on the other hand, showed minimal alterations in molecular features, while displaying positive 304 
adjustments in terms of respiration and calcium loading capacity, two measures of functional changes.  305 
By using sequential Principal Component Analysis and Feature Correlation Analysis, we demonstrated for 306 
the first time alterations in sets of transcripts and proteins, but not in functional measurements, that might 307 
serve as potential early acute markers of cardiac-specific mitochondrial toxicity, contributing to explain the 308 
trajectory of DOX cardiac toxicity and to measure the efficacy of novel interventions aimed at minimizing 309 
DOX cardiac liabilities in anti-cancer treatments (Pereira, et al., 2012; Pereira, et al., 2016). Nonetheless, 310 
longer resting periods after DOX-acute treatment should be studied to determine when mitochondrial 311 
functional impairments begin to be apparent in the different organs studied. Similarly, it remains to be 312 
elucidated whether these molecular markers are detectable in the circulation of DOX-treated animals or 313 
patients. Although mRNA has become a signature-based biomarker in cancer management, their use in 314 
cardiovascular medicine is still in its earlier days; however, it would prove instrumental in the early detection 315 
of DOX-induced cardiotoxicity in the clinic and could replace myocardial biopsies, an invasive procedure to 316 
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MATERIALS AND METHODS 330 
Reagents 331 
DOX hydrochloride, (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-332 
trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione hydrochloride, chemical 333 
purity ≥ 98%, was obtained from Sigma-Aldrich (Barcelona, Spain) and prepared in a sterile saline solution, 334 
NaCl 0.9% (pH 3.0, HCl) and stored at 4ºC for no longer than five days upon re-hydration. All other 335 
chemicals were of the highest commercially available grade of purity. Aqueous solutions were prepared in 336 
ultrapure (type I) water (Milli-Q Biocel A10 with pre-treatment via Elix 5, Millipore, Billerica, MA, USA). 337 
For non-aqueous solutions, ethanol (99.5%) or dimetylsulfoxide (DMSO), both from Sigma-Aldrich, were 338 
used as solvent.  339 
 340 
Animal care 341 
Animal handling was performed in accordance with the European Convention for the Protection of Vertebrate 342 
Animals used for Experimental and Other Scientific Purposes (CETS no.123) and Portuguese rules (DL 343 
129/92). The procedures were approved by the CNC Committee for Animal Welfare and Protection. Animal 344 
handlers and the authors GCP, SPP, JM, AA and PJO are credited by the European Federation for Laboratory 345 
Animal Research (FELASA) category C for animal experimentation (accreditation no. 020/08).  346 
Male Wistar rats, Crl:WI(Han), were purchased from Charles River (France) with 14 weeks of age, 347 
acclimated for 10-14 days prior to the initiation of experiments and maintained in the local animal house 348 
facility (CNC – School of Medicine, University of Coimbra, Coimbra, Portugal). Animals were group-housed 349 
in type III-H cages (Tecniplast, Italy) with irradiated corn cob grit bedding (Scobis Due, Mucedola, Italy) and 350 
environmental enrichment and under controlled environmental requirements (22ºC, 45-65% humidity, 15-20 351 
air changes/hour, 12 h artificial light/dark cycle, noise level < 55 dB) and free access to standard rodent food 352 
(4RF21 GLP certificate, Mucedola, Italy) and acidified water (at pH 2.6 with HCl) ad libitum.  353 
The experimental model was performed as previously described (Pereira, et al., 2012). Briefly, male Wistar-354 
Han rats (N = 34) were randomly divided into two groups (n = 17 each group) and received a single 355 
intraperitoneal injection (i.p.) of DOX (20 mg/Kg of body weight) or an equivalent volume of vehicle solution 356 




All animals were injected during the light phase of the cycle and weighed at the beginning and end of the 358 
experimental treatment period (data available in Pereira, et al. (2012)). Non-fasted animals were euthanized in 359 
pairs by cervical dislocation followed by decapitation, to confirm death and exsanguination. Organs were 360 
immediately extracted from the body and quickly washed in appropriate ice-cold buffer before being weighed 361 
(data available in Pereira, et al. (2012)). Tissues intended for mRNA and protein analyses were stored 362 
separately in RNAlater (Applied Biosystems/Ambion, Austin, TX) at –80°C, accordingly to manufacturer 363 
guidelines. 364 
 365 
Isolation of mitochondrial fraction 366 
Mitochondria were isolated by a standard procedure currently used in our laboratory (Pereira, et al., 2012). 367 
Briefly, organs were excised and finely minced in ice-cold isolation medium containing 250 mM sucrose, 10 368 
mM HEPES, 1 mM EGTA and 0.1% defatted BSA (pH 7.4, KOH). After washing the blood, organs were 369 
homogenized with a motor-driven Teflon Potter homogenizer. For the isolation of cardiac mitochondrial 370 
fractions, isolation medium was supplemented with 0.5 μg/mL of protease (Subtilisin A, Type VIII from 371 
Bacillus licheniformis, Sigma-Aldrich, Madrid, Spain). Protease was removed from the cardiac homogenate 372 
by centrifugation at 14,400 g for 10 min at 4°C and the pellet, essentially devoid of protease, was gently 373 
homogenized and resuspended to its original volume with a loose-fitting homogenizer. Subsequently, all 374 
homogenates were centrifuged at 750 g for 10 min at 4°C and the resulting supernatants at 10,000 g for 10 375 
min. Mitochondrial pellet was resuspended using a paintbrush and centrifuged twice at 10,000 g for 10 min 376 
before obtaining a pure mitochondrial suspension. EGTA and defatted BSA were omitted from the final 377 
washing medium (pH 7.2, KOH). Mitochondrial protein was quantified by the biuret method using bovine 378 
serum albumin (BSA) as standard. Mitochondrial preparations were kept on ice during experiments, which 379 
were carried out after 20 min recovery period and within 5 h. The respiratory control ratio (RCR) values of 380 
the mitochondrial preparations were within the standard range, demonstrating a good coupling between 381 
respiration and ATP phosphorylation (Heart saline glutamate plus malate 4.6 ± 0.4, succinate 2.7 ± 0.2; Liver 382 
saline glutamate plus malate 9.5 ± 1.0, succinate 8.2 ± 1.5; Kidney saline glutamate plus malate 4.1 ± 0.3, 383 
succinate 3.5 ± 0.2; there was no statistical difference between saline vs. DOX group), previously reported in 384 





Measurement of hydrogen peroxide 387 
H2O2 generation was measured fluorimetrically using a modified method previously described by Barja 388 
(2002). Briefly, the method consists in the use of homovanillic acid which reacts with H2O2 in the presence of 389 
horseradish peroxidase to form the fluorescent dimer 2,2’-dihydroxy-3,3’-dimethoxydiphenyl-5,5’-diacetic 390 
acid (λEx/λEm = 312/420 nm). Reactions (500 μL) were conducted in standard glass test tubes under constant 391 
magnetic stirring and incubated in a water bath at 30°C. Small volumes of reactants were combined in the 392 
following order to pre-added incubation medium (145 mM KCl, 30 mM Hepes [pH 7.4, KOH], 5 mM 393 
KH2PO4, 3 mM MgCl2, 100 μM EGTA, 0.1% fatty acid-free albumin) to reach the following concentrations: 394 
0.125 μg mitochondrial protein, 6 U/mL horseradish peroxidase and 100 μM homovanillic acid. H2O2 395 
production was determined in mitochondria energized with 5 mM glutamate/malate or 5 mM succinate. At 396 
these concentrations, H2O2 production is not substrate-dependent. In some experiments, specific inhibitors for 397 
Complex I (rotenone, 1 μM) or for Complex III (antimycin A, 0.5 μM) were used in combination with 398 
respiratory substrates to block electron transport and maximize H2O2 production. Arbitrary fluorescence units 399 
were converted to nmol H2O2 by extrapolation through a standard curve established by addition of known 400 
amounts of H2O2 in the presence of horseradish peroxidase and homovanillic acid. Values were then 401 
normalized to protein amount and expressed as nmol H2O2/15 min/mg protein.  402 
 403 
Mitochondrial Calcium Accumulation 404 
Extramitochondrial free Ca2+ was assayed by monitoring the variations in fluorescence of the hexapotassium 405 
salt of the probe Calcium Green 5-N (Ca5GN; Invitrogen, Spain, C-3737), which increases its yield upon 406 
binding to calcium, and as previously described (Rajdev et al., 1993). Briefly, isolated mitochondrial fraction 407 
(0.25 mg/mL cardiac, 0.75 mg/mL liver and kidney) were suspended in 2 mL of buffer containing 200 mM 408 
sucrose, 10 mM Tris, 10 μM EGTA (to complex basal calcium), 5 mM KH2PO4 for cardiac mitochondria, or 409 
1 mM KH2PO4 for liver and kidney mitochondria, combined with 812 nM of Ca5GN. After mitochondrial 410 
energization with 2.5 mM glutamate plus malate (enabling mitochondrial energization through complex I) or 411 
2.5 mM succinate in the presence of 1 μM rotenone (enabling mitochondrial energization through complex II) 412 




nmol and 40-65 nmol for heart, liver and kidney mitochondria. Fluorescence was continuously recorded in a 414 
water-jacketed cuvette holder at 30°C using a PerkinElmer LS-55 fluorescence spectrometer (PerkinElmer 415 
Life and Analytical Sciences, Boston, MA) at λEx/λEm = 506/531 nm. Five nm slits were used for excitation 416 
and emission wavelengths. Adequate controls were performed to assess possible interferences in probe 417 
fluorescence, under either low or high calcium concentrations (no interferences were observed for the 418 
experimental conditions described). Possible interferences with DOX were discarded since its emission peaks 419 
at 550 nm, a higher wavelength than our emission filter; and, excitation peaks at 475 nm, meaning that only a 420 
small fraction of the drug could lower Ca5GN excitation at 506 nm. Cyclosporin A (CsA), a desensitizer of 421 
the mPTP (Broekemeier, et al., 1989), was used to confirm that the recorded event was related to the mPTP. 422 
 423 
Calcium-induced mitochondrial swelling 424 
Mitochondrial osmotic volume changes associated with the calcium-induced mPTP were assessed by 425 
turbidimetry (Halestrap et al., 1990). The optical density was monitored at 540 nm with a Jasco V-560 426 
spectrophotometer (Jasco Inc., Easton, MD, USA) equipped with a magnetic stirrer and a water-jacketed 427 
cuvette holder connected to a water bath set to 30°C. The assay was carried out in the same buffer as 428 
described above for calcium loading experiments, but at a protein concentration of 0.5 mg/mL (heart) or 1.0 429 
mg/mL (liver and kidney) was used. After a 60 sec baseline, a single pulse of calcium of 20-50 nmol/mg 430 
protein or 10-50 nmol/mg protein was added to heart or liver and kidney mitochondria, respectively. 431 
Absorbance variations were recorded and analyzed with the manufacturer’s software. The swelling amplitude 432 
presented in the graphs is defined as the difference in absorbance between the time-point that corresponds to 433 
half of the maximum swelling amplitude of the control record and the baseline before calcium addition (larger 434 
values mean greater sensitivity to mPTP). CsA was used to confirm that the recorded events were related to 435 
the mPTP. 436 
 437 
Total RNA isolation 438 
RNA was isolated using the RNeasy Mini Kit (Qiagen Inc., Valencia, CA). Briefly, 20 mg of each RNAlater-439 
conserved frozen tissue was thawed and ground in a glass pestle homogenizer followed by further 440 




in the manufacturer’s RNA clean-up protocol, following its suggestions. RNA was quantified using a 442 
NanoDrop spectrophotometer (ThermoFisher Scientific Inc., Rockford, IL). RNA quality and purity were 443 
assessed by observing a spectral scan with a single prominent A260 peak and A260/A280 ratio greater than 2. 444 
Protein extraction and Western blot 445 
RNAlater-conserved frozen tissue (70-150 mg) was thawed and ground in a glass pestle homogenizer in a 446 
10% (m/v) RIPA buffer (150 mM NaCl, 50 mMTris, pH 8.8, 0.5% sodium deoxycholate, 0.1% SDS, and 1% 447 
Igepal), supplemented with 5 μL/mg of tissue of protease inhibitors cocktail (P8340, Sigma-Aldrich Inc, St. 448 
Louis, MO, USA). The homogenate was then centrifuged at 14,000 g for 5 min to remove cellular debris. 449 
Protein concentration was determined by BCA Protein Assay Kit (Thermo Fisher Scientific Inc.) using BSA 450 
as standard. Extracted proteins were diluted in Laemmli buffer (BioRad Laboratories, Hercules, CA, USA) 451 
supplemented with 2% β-mercaptoethanol then boiled at 95ºC for 5 min. Equal amounts of protein (25 μg) 452 
were loaded into 12% polyacrylamide gels separated by SDS-PAGE. Then, proteins were transferred to 453 
PVDF membranes (Millipore, Billerica, Massachusetts, USA) at 100 V for 90 min, at 4ºC. Membranes were 454 
blocked with 0.25% of non-fat dry milk in Tris-buffered saline (154 mM NaCl, 50 mM Tris, pH 8.0) 455 
containing 0.1% Tween-20 (TBS-T) using the SNAP-id system (Millipore) with 10 min incubation. After 456 
washing twice with TBS-T in the same system, membranes were incubated with primary antibody directed 457 
against the respective protein (listed in Table S1) through traditional procedures, overnight at 4ºC. After 458 
washing twice in the SNAP-id system, membranes were incubated in this system with the respective alkaline 459 
phosphatase-linked secondary antibody (1:6000), prepared in TBS-T. The membranes were processed for 460 
protein detection using the Enhanced Chemi-Fluorescence system (ECF; GE Healthcare, Buckinghamshire, 461 
UK) and imaged with the Versa Doc imaging system (BioRad). The densities of each band were calculated 462 
with Quantity One Software (BioRad) and expressed as a percentage of control. The assay was standardized 463 
by re-probing the membranes for actin (#MAB1501, Milipore) immunoreactivity (1:10,000) to verify whether 464 
similar amounts of protein present in all lanes. 465 
 466 
Real time qRT-PCR 467 
cDNA was synthesized from extracted RNA (0.5–1.5 μg) using random primers along with the Omniscript 468 




the web-based PrimerQuest software (Integrated DNA Technologies, Inc., Coralville, IA). Real time qRT-470 
PCR was carried out using FastStart SYBR Green I Kit (Roche Diagnostics, Indianapolis, IN) with 10 μL 471 
reaction volume and performed in a LightCycler (Roche Diagnostics). Quantitation of gene expression was 472 
achieved by measuring target messenger RNA (mRNA) copy number against a 10-fold serial dilution of 473 
target-specific DNA standard ranging between 107 and 103 DNA copies. A target-specific DNA standard was 474 
prepared for each transcript by performing a 150 μl PCR reaction using HotstarTaq PCR Master Mix Kit 475 
(Qiagen) and cleaning the product using the Qiaquick PCR Purification Kit (Qiagen) The purified DNA 476 
standard was visualized by running a 100 ng aliquot on a 1.5% agarose gel and verifying that a single product 477 
of the proper size was present. The DNA standard was quantified spectrophotometrically using the NanoDrop 478 
ND1000 and diluted to a standard stock concentration of 5 × 109 DNA copies per microliter. 18S ribosomal 479 
RNA was used to normalize gene expression. Real-time qRT-PCR of control and treated samples for each 480 
gene was performed on the same run to minimize potential run to run variability. 481 
 482 
Exploratory analysis and data statistical analysis 483 
Results are shown as means ± SEM of the indicated number of experiments. Statistical significance between 484 
mean differences was determined using two-tailed Student’s t test after normality and homogeneity of 485 
variances was access using a Shapiro-Wilk and Levene’s test. Control group was matched against the treated 486 
group for each day to exclude the variability associated with mitochondrial isolation. In the specific case 487 
when seeking to ascertain whether changes between saline and DOX group in the heart are actually different 488 
from changes in other tissues, regardless of the inter-tissue baseline (i.e. for mRNA) data were analyzed by a 489 
two-way ANOVA with planned contrasts against the interaction between treatment and tissue so that 490 
significant relative changes (fold-change) are dependent on tissue. p-Values were thereafter adjusted for 491 
multiplicity using Šídák post-hoc test. Differences were considered significant if p < 0.05 and categorized 492 
accordingly to their interval of confidence. Statistical analyses were performed using Graph Pad Prism 493 
version 5.0 (GraphPad Software, Inc., San Diego, CA, USA), except of the two-way ANOVA, which was 494 





The exploratory analysis comprises the application of Feature Correlation Analysis (FCA) and Principal 497 
Component Analysis (PCA) methods. For both studies, samples with missing values were discarded. 498 
Standardization was applied to all the remaining features and the corresponding standard scores were used. 499 
FCA was performed using the Pearson correlation coefficients, whose values belong to the interval [-1, +1]: 500 
+1 signals a total positive linear correlation, 0 identifies no linear correlation and -1 refers to a total negative 501 
linear correlation. To simplify the analysis of the results, we consider just the absolute magnitude of change 502 
and created several graphical displays of the correlation matrices.  503 
PCA was applied to find the two principal components that collectively explain most of the variability of the 504 
original set. The obtained eigenvectors were used to project the original samples in a set of 2D plots. Both 505 
FCA and PCA studies were performed using Python2, version 7. We relied on the Pandas package to load, 506 
store and transform the data (McKinney, 2010). The statistical analysis was performed using SciPy (Jones, 507 
2001) and scikit-learn (Fabian Pedregosa, 2011). FCA correlation plots were created using Matplotlib and 508 
Biokit modules (Hunter, 2007). PCA scatter plots and density region charts were obtained with Orange Biolab 509 
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Table 1 - Effect of cyclosporin A (CsA) on calcium-induced mPTP evaluated with Ca5GN. 656 
Substrate Treat. Heart Liver Kidney 












  % of inhibition 
  nCsA = 4 nCsA = 6 nCsA = 5 
Glutamate/Malate Saline 85.9** 25.0 107.0*** 21.0 98.8*** 17.0 
DOX 96.4** 24.6 101.0*** 22.0 96.0** 24.4 
Succinate Saline 92.2* 37.2 72.6*** 11.7 101.4** 23.7 
DOX 97.0* 39.6 100.0* 32.0 98.5** 21.9 
 657 
Tabulated values represent the difference between means of groups in the absence of CsA and groups with 658 
CsA, e.g. saline-glutamate/malate vs. saline-glutamate/malate + CsA, and are expressed as relative percentage 659 
to the group without CsA. *, p ≤ 0.05; **, p ≤ 0.01 and ***, p ≤ 0.001 vs. group with CsA, as evaluated by an 660 
unpaired Student’s t test. Abbreviations: Exp. – experimental setup; Treat. - treatment; Diff. Means - 661 






Table 2 - Effect of CsA on calcium-induced mitochondrial swelling. 665 
Substrate Treat. Heart Liver Kidney 












  % of inhibition 
  nCsA = 4 nCsA = 6 nCsA = 5 
Glutamate/Malate Saline 80.6* 34.8 108.6*** 24.8 87.0** 23.6 
DOX 76.6** 33.7 80.9** 22.2 90.7** 25.3 
Succinate Saline 91.6*** 14.4 99.0*** 38.3 88.0** 18.9 
DOX 93.8** 28.7 98.1* 29.3 87.3** 20.5 
 666 
Tabulated values represent the difference between means of groups in the absence of CsA and groups with 667 
CsA, e.g. saline-glutamate/malate vs. saline-glutamate/malate + CsA, and are expressed as relative percentage 668 
to the group without CsA. *, p ≤ 0.05; **, p ≤ 0.01 and ***, p ≤ 0.001 vs. group with CsA, as evaluated by an 669 
unpaired Student’s t test. Abbreviations: Exp. – experimental setup; Treat. - treatment; Diff. Means - 670 





Table 3 - Effects of DOX treatment on protein content of mPTP-related proteins. 673 
    ANT VDAC Cyp-D 
    Mean SE Mean SE Mean SE 
Heart Saline 1.02 0.05 0.96 0.02 1.00 0.03 
DOX 0.97 0.08 1.04 0.05 1.01 0.02 
Liver Saline 0.97 0.08 1.00 0.10 1.00 0.07 
DOX 1.04 0.04 0.99 0.08 1.01 0.04 
Kidney Saline 1.02 0.05 0.95 0.11 1.06 0.04 
DOX 0.99 0.05 1.04 0.08 0.95 0.05 
 674 
Protein levels data are presented as arbitrary units and represent densitometry analysis of western blot 675 
membranes after image acquisition. Differences between treatment group means were evaluated by matched 676 





Table 4 – Effects of DOX treatment on transcript level of mPTP-related proteins. 679 
    ANT1 ANT2 VDAC1 VDAC2 VDAC3 


































































































































Total mRNA was extracted from each tissue and transcript levels were analyzed through RT-qPCR with the 681 
transcript copy number being thereafter normalized to 18S copy number. Values are shown as transcript copy 682 
number / 18S copy number. For statistical analysis, tabulated values were log transformed and differences in 683 
fold-change of each tissue were detected by a two-way ANOVA with planned contrasts and adjusted for 684 
multiple comparisons through the Sidak test. a , p ≤ 0.05 Saline-DOX fold-change in heart vs liver and 685 
Saline-DOX fold-change  in heart vs. kidney; b , p ≤ 0.05 Saline-DOX fold-change in heart vs. kidney. n = 6 686 






FIGURE SUBTITLES 690 
Fig. 1: PCA projection along the two principal components of the separation between DOX (red) and Saline 691 
(blue) samples for Heart (a), Kidney (b) and Liver (c). The two class density colors identify the area of 692 
influence of each group. The four panels in each figure display results obtained with each mitochondrial 693 
respiratory complex. PCA was performed on transcripts (mRNA) of genes encoding proteins from 694 
mitochondrial Complexes I-IV. The study was based on 12 samples (6 Saline and 6 DOX) and 13, 4, 6, and 7 695 
transcripts for each one of the 4 respiratory complexes (I-IV), respectively. PCA was performed separately for 696 
each combination of tissue and specific respiratory chain complex, to simplify the identification of situations 697 
in which a clear boundary between the two treatment groups emerges. 698 
 699 
Fig.2: Matrices with all correlation changes in the features that result from the administration of DOX: a - 700 
Heart; b - Kidney; c - Liver. Blank cells indicate that there is no significant change in correlation levels 701 
calculated before and after DOX treatment. Cells with circles identify sizable changes in the correlation value. 702 
The area and shading of a circle are directly proportional to the absolute magnitude of change. 703 
 704 
Fig. 3: Effects of DOX treatment on mitochondrial H2O2 production. After 15 min, end-point H2O2 levels 705 
were measured fluorimetrically through reaction with homovalinic acid. a - heart; b - liver; c - kidney. Circles 706 
represent means of treatment groups (saline in white circles; DOX in black circles) with SEM (error bars are 707 
smaller than symbols when not visible). Differences between means of treatment were evaluated by matched 708 
pairs Student’s t test to exclude the variability related to mitochondrial. ∗p ≤ 0.05 and ∗∗p ≤ 0.01 vs saline 709 
group of the same model. n = 8, 7 and 6 (heart, liver and kidney, respectively). 710 
 711 
Fig. 4: Effects of DOX treatment on mitochondrial calcium-loading capacity. Ca2+ movements were evaluated 712 
using the extramitochondrial fluorescent probe Ca5GN after addition of a single pulse of Ca2+. The retention 713 
time is defined by the time interval between the influx and efflux of Ca2+ whose fluorescence value equals the 714 
peak half-height fluorescence upon addition of calcium (larger values mean less sensitivity to mPTP). a - 715 
heart; b - liver; c - kidney. Bars represent means of treatment groups (saline in white bars; DOX in black bars) 716 




to exclude the variability related to mitochondrial isolation. ∗p ≤ 0.05 and ∗∗p ≤ 0.01 vs saline group. n = 10, 718 
9 and 10 (heart, liver and kidney, respectively). GM, glutamate/malate; SUC, succinate. 719 
 720 
Fig. 5: Effects of DOX treatment on calcium-induced mitochondrial swelling. Mitochondrial swelling was 721 
evaluated by following the decrease in apparent absorbance of the mitochondrial suspension at 540 nm after 722 
addition of a single pulse of Ca2+. The swelling amplitude presented in the graphs is defined as the difference 723 
in absorbance between the point which corresponds to half of the maximum swelling amplitude of the control 724 
record and the maximum absorbance before calcium addition (larger values mean greater sensitivity to 725 
mPTP). a - heart; b - liver; c - kidney. Bars represent means of treatment groups (saline in white bars; DOX in 726 
black bars) with SEM. Differences between means of treatment groups were evaluated by matched pairs 727 
Student’s t test to exclude the variability related to mitochondrial isolation. ∗p ≤ 0.05 vs saline group of the 728 
same model. n = 10, 9 and 10 (heart, liver and kidney, respectively). GM, glutamate/malate; SUC, succinate. 729 










Figure 2A 734 
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Figure 2B 737 
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Figure 2C 740 
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Figure 5 749 
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